Zion Market Research has published a new report titled “STD Diagnostics Market by Type (Chlamydia Testing, Syphilis Testing, Gonorrhea Testing, Herpes Simplex Virus Testing, Human Papilloma Virus Testing, Human Immunodeficiency Virus Testing and Others) and by Testing Devices (Laboratory Devices and Point of Care Devices) for Hospitals and Other End Users – Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global STD diagnostic market accounted for approximately USD 103.20 billion in 2015 and is expected to reach around USD 166.50 by 2021, growing at a CAGR of around 8.3% between 2015 and 2021.

The term ‘Sexually Transmitted Diseases’ refers to a group of illnesses that can be transmitted from one person to another through the sharing of body fluids, vaginal fluids, blood, and others. The term sexually transmitted disease include more than 25-30 infectious diseases that are spread through sexual activity. Most people with STDs have no symptoms. Without treatment, these diseases can lead to major health problems such as not being able to get pregnant (infertility), permanent brain damage, heart disease, cancer, and even death. If the patient has been exposed to a sexually transmitted disease he should visit a health clinic, hospital or doctor for testing and treatment. Common sexual transmitted diseases include chlamydia, syphilis, gonorrhea, herpes simplex virus, human papilloma virus, human immunodeficiency virus and others.

Browse the full report at https://www.zionmarketresearch.com/report/std-diagnostics-market

The sexual transmitted diagnostic test market was expected to witness the highest growth over the forecast period due to increasing percentage of HIV/HPV infected population across the globe. Furthermore, increasing the incidence of weakened immune system coupled with unprotected sex is also considered as a major governing factor which promotes the cause of sexually transmitted diseases and thus promotes the STDs diagnostic market. Moreover, increasing demand for rapid and accurate diagnostic tests and presence of favorable government initiatives for STD testing in developing countries such as Brazil, India, and China are further estimated to boost the market growth of STDs diagnostic market. However, the high cost of diagnostic test considered as a major restraining which hindered the growth of STDs diagnostic market. In addition, the unwillingness of the infected population, discontinuation of therapy coupled with the psychological impact of sexual transmitted are also considered as a key restraining factor which may curb the growth of STDs diagnostic market.

Based on the type, the global market of STD diagnostic test is bifurcated into seven types: chlamydia testing, syphilis testing, gonorrhea testing, herpes simplex virus testing, human papilloma virus testing, human immunodeficiency virus testing and others. HPV caused cervical cancer is a commonly found and most prevalent cancer among women.  HPV 16 and HPV 18 is a most common causative agent which in approximately 99% of women affected by cervical cancer. Every year, around 300,000 cervical cancer deaths are registered due to HPV. The HIV segment is expected to be the fastest-growing segment of the global STD diagnostic testing market in the years to come predicted to expand at a CAGR of around 10%.

Based on end-user, the global market of STD diagnostic test is bifurcated into two types: hospital and others. In the end-user segment, the hospital was the leading segment in 2015 and this segment is expected to show continuous growth during the forecast period due to the continuous rise in HPV virus across the globe.

Based on the testing device, the global market of STD diagnostic test is bifurcated into two types: laboratory testing device and point of care device. The laboratory testing device market is further segmented into thermal cyclers – PCR, lateral flow readers – immunochromatographic assays, flow cytometers, differential light scattering machines, absorbance microplate reader – Enzyme-Linked Immunosorbent Assay (ELISA) and others. In testing device segment, laboratory testing was the leading segment in 2015 and this segment is projected to dominate STD diagnostic test market during the forecast period due to the continuous rise in HPV/HIV virus related infection across the globe. POC tests do not identify all STDs and many of these methods don’t follow the standard regulatory norms. Hence, laboratory methods are highly significant and reliable.

In terms of geography, North America was the leading market for sexual transmitted diseases diagnostic market in 2015 in terms of revenue due to the availability of technologically advanced computer-guided screening tests. North America and Europe has the high prevalence of Chlamydia, P&S Syphilis and Gonorrhea and holds the largest share for testing of these infections in this region. Furthermore, lifestyle-related factors such as having multiple sex partners, is very common in the US, and European countries which lead to the increase in the prevalence of sexually transmitted infection. Asia Pacific is expected to be the fastest growing regional segment for the STDs diagnostic test market in 2015 within the forecast period due to rapid spread of Human Papilloma Virus (HPV) infection among the female population in this region.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global STD diagnostics market include Roche Holdings AG, Abbott Laboratories, Becton Dickinson and Company, Hologic Inc., Danaher Corporation, Affymetrix, bioMerieux, Cepheid Inc., Alere Inc., DiaSorin, and Orasure.